Albertsons® Companies, Inc. Reports Fourth Quarter and Full Year Results

About this update from Albertsons Companies, Inc.

Announces 13% Increase in Common Stock Dividend Increases Remaining Share Repurchase Authorization to $2 billion Provides Fiscal 2026 Outlook BOISE, Idaho, April 14, 2026 --( BUSINESS WIRE )--Albertsons® Companies, Inc. (NYSE: ACI) (the "Company") today reported results for the fourth quarter of fiscal 2025 and full year fiscal 2025, which ended Feb. 28, 2026 and included 13 and 53 weeks, respectively. Fourth Quarter of Fiscal 2025 Highlights Fiscal 2025 Highlights "Fiscal 2025 was a year of disciplined execution and resilience, as we closed the year with a solid fourth quarter that delivered strong Adjusted EBITDA despite meaningful top-line pharmacy-related headwinds," said Susan Morris, CEO of Albertsons Companies. Morris continued, "Across the full year, we remained focused on building a stronger foundation for the future, including investing in our customer value proposition, advancing digital and loyalty, and strengthening the capabilities that support sustainable, long-term growth. As we enter fiscal 2026, we are building on this foundation by scaling our productivity engine and positioning the company to deliver earnings growth, strong cash flow, and long-term shareholder returns." Fourth Quarter of Fiscal 2025 Results Net sales and other revenue was $20.3 billion for the 13 weeks ended Feb. 28, 2026 ("fourth quarter of fiscal 2025") compared to $18.8 billion during the 12 weeks ended Feb. 22, 2025 ("fourth quarter of fiscal 2024"). The increase included approximately $1.4 billion incremental net sales related to the extra week in the fourth quarter of fiscal 2025. Identical sales increased 0.7%, primarily driven by pharmacy sales, which were impacted more than expected by the pricing headwinds related to the Inflation Reduction Act ("IRA") and a mix shift within the broader pharmacy industry. The Company also continued to grow its digital sales with a 16% sales increase during the fourth quarter of fiscal 2025. These increases in Net sales and other revenue were partially offset by a net reduction in sales driven by store closures since the fourth quarter of fiscal 2024. Gross margin rate decreased to 27.2% during the fourth quarter of fiscal 2025 compared to 27.4% during the fourth quarter of fiscal 2024. Excluding the impact of fuel and LIFO, gross margin rate decreased 25 basis points compared to the fourth quarter of fiscal 2024. This decrease in gross margin rate was primarily driven by increases in delivery and handling costs related to the continued growth in digital sales. Gross margin rate during the fourth quarter of fiscal 2025 was favorably impacted by improvements in pharmacy gross margins, primarily driven by changes related to the IRA. The Company also continues to make incremental investments in its customer value proposition which were funded by the benefits from its productivity initiatives. Selling and administrative expenses increased to 29.6% of Net sales and other revenue during the fourth quarter of fiscal 2025 compared to 25.7% during the fourth quarter of fiscal 2024. Excluding the impacts of fuel and the charge related to the Opioid Settlement Framework, Selling and administrative expenses as a percentage of Net sales and other revenue decreased two basis points, reflecting the Company's continued disciplined approach to productivity and cost management, despite the lower-than-expected pharmacy sales and the resulting effect on the rate. Net loss on property dispositions and impairment losses was $16.5 million during the fourth quarter of fiscal 2025 compared to $36.4 million during the fourth quarter of fiscal 2024. Interest expense, net was $141.1 million during the fourth quarter of fiscal 2025 compared to $101.5 million during the fourth quarter of fiscal 2024. The increase in interest expense, net was primarily attributable to higher average outstanding borrowings. Other income, net was $6.8 million during the fourth quarter of fiscal 2025 compared to $43.7 million during the fourth quarter of fiscal 2024. Income tax benefit was $160.2 million during the fourth quarter of fiscal 2025, representing a 25.0% effective tax rate, and was the result of the loss before income taxes which was driven by the $773.8 million charge during the fourth quarter of fiscal 2025 related to the Opioid Settlement Framework. Income tax expense was $46.4 million during the fourth quarter of fiscal 2024, representing a 21.3% effective tax rate. Net loss was $(480.8) million or $(0.94) per share during the fourth quarter of fiscal 2025 compared to net income of $171.8 million or $0.29 per share during the fourth quarter of fiscal 2024. Net loss during the fourth quarter of fiscal 2025 included the $599.8 million charge, net of tax, or $(1.18) per share, related to the Opioid Settlement Framework. Adjusted net income was $251.7 million, or $0.48 per share during the fourth quarter of fiscal 2025 compared to $269.5 million, or $0.46 per share during the fourth quarter of fiscal 2024. Adjusted net income per share during the fourth quarter of fiscal 2025 includes an estimated incremental $0.03 per share related to the extra week in the fourth quarter of fiscal 2025. Adjusted EBITDA was $903.4 million during the fourth quarter of fiscal 2025 compared to $855.1 million during the fourth quarter of fiscal 2024. The increase in Adjusted EBITDA reflects an estimated incremental $68 million related to the extra week in the fourth quarter of fiscal 2025. Opioid Settlement Framework In the fourth quarter of fiscal 2025, the Company recorded a loss of $773.8 million ($599.8 million, net of tax) related to the opioid settlement framework announced today that is intended to resolve substantially all of the opioid-related claims that have been or may be asserted against the Company by participating states, political subdivisions and Native American tribes (the "Opioid Settlement Framework"). Payments are expected to be made over a period of nine years. For more information, please refer to the separate press release issued this morning. Capital Allocation, Common Stock Repurchase Program and Debt Refinancing During fiscal 2025, capital expenditures were $1,839.4 million, which primarily included the completion of 94 remodels, the opening of nine new stores and continued investment in the Company's digital and technology platforms. During the fourth quarter of fiscal 2025, the Company paid its quarterly dividend of $0.15 per share on Feb. 6, 2026 to stockholders of record as of Jan. 23, 2026. On April 14, 2026 subsequent to the end of the fourth quarter of fiscal 2025, the Company announced that the Board of Directors (the "Board") increased the quarterly cash dividend 13% from $0.15 per common share to $0.17 per common share. On April 14, 2026, the Company announced the next quarterly dividend payment of $0.17 per share of Class A common stock to be paid on May 8, 2026 to stockholders of record as of the close of business on April 24, 2026. On Jan. 8, 2026, the Company's previously announced $750 million accelerated share purchase agreement (the "ASR Agreement") was completed, and the Company received a final delivery of 7.3 million shares of common stock. As a result, the Company received a total of 42.7 million shares of common stock during the ASR Agreement, inclusive of the 35.4 million initial shares received during the third quarter of fiscal 2025. During fiscal 2025, inclusive of the ASR Agreement, the Company invested $1,492.5 million related to the repurchase of 78.7 million shares of common stock pursuant to the existing multi-year repurchase authorization. On April 14, 2026, the Company announced that the Board has authorized an increase to the remaining share repurchase authorization of $900 million, resulting in a total remaining authorization of $2.0 billion. The share repurchase program could include open market repurchases, accelerated share repurchase programs, tender offers, block trades, potential privately negotiated transactions, or trading plans in compliance with the federal securities laws. On Feb. 2, 2026, the Company completed the issuance of $1,200.0 million aggregate principal amount of 5.625% senior unsecured notes due March 31, 2032 (the "2032 Notes") and $900.0 million aggregate principal amount of additional 5.750% senior notes due March 31, 2034 (the "Additional 2034 Notes" and together with the 2032 Notes, the "Notes"). During the fourth quarter of fiscal 2025, proceeds from the Notes were used to redeem in full the $1,350.0 million outstanding of the Company's 4.625% senior unsecured notes due Jan. 15, 2027, to redeem in full the $750.0 million outstanding of the Company's 5.875% senior unsecured notes due Feb. 15, 2028 (the "Redemptions"), and to pay fees and expenses related to the Redemptions and the issuance of the Notes. Fiscal 2026 Outlook The Company is providing its fiscal 2026 outlook as follows: The Company is unable to provide a full reconciliation of the GAAP and Non-GAAP Measures (as defined below) used in the fiscal 2026 outlook without unreasonable effort because it is not possible to predict certain of the adjustment items with a reasonable degree of certainty. This information is dependent upon future events and may be outside of the Company's control and could have a significant impact on its GAAP financial results for fiscal 2026. The expected effective tax rate does not reflect potential future rate adjustments for the resolution of tax audits or potential changes in tax laws, which cannot be predicted with reasonable certainty. Conference Call The Company will hold a conference call today at 8:30 a.m. Eastern Time, which will be hosted by Susan Morris, CEO, and Sharon McCollam, President & CFO. The call will be webcast and can be accessed at https://albertsonscompanies.com/investors/events-and-presentations . A replay of the webcast will be available for at least two weeks following the completion of the call. About Albertsons Companies Albertsons Companies is a leading food and drug retailer in the United States. As of Feb. 28, 2026, the Company operated 2,244 retail stores with 1,713 in-store pharmacies, 405 associated fuel centers, 22 dedicated distribution centers and 19 manufacturing facilities. The Company operates stores across 35 states and the District of Columbia under 22 well known banners including Albertsons, Safeway, Vons, Jewel-Osco, Shaw's, ACME, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen, Carrs, Kings Food Markets and Balducci's Food Lovers Market. The Company is committed to helping people across the country live better lives by making a meaningful difference, neighborhood by neighborhood. In 2025, along with the Albertsons Companies Foundation, the Company contributed $497 million in food and financial support, including $56 million through its Nourishing Neighbors Program to ensure those living in its communities and those impacted by disasters have enough to eat. Albertsons, Safeway, Vons, Jewel-Osco, Tom Thumb, Randalls, United Supermarkets, Pavilions, Haggen and Balducci's Food Lovers Market are registered trademarks of Albertsons Companies Inc. or its subsidiaries. ACME, Carrs, Kings Food Markets, Shaw's and Star Market are trademarks of Albertsons Companies Inc. or its subsidiaries. Albertsons associated logos, product names and services are trademarks of Albertsons Companies, Inc. All other trademarks are the property of their respective owners. Forward-Looking Statements and Factors That Impact the Company's Operating Results and Trends This press release includes "forward-looking statements" within the meaning of the federal securities laws. The "forward-looking statements" include the Company's current expectations, assumptions, estimates and projections about its business and its industry. They include statements relating to the Company's future operating or financial performance which the Company believes to be reasonable at this time. You can identify forward-looking statements by the use of words such as "outlook," "may," "should," "could," "estimates," "predicts," "potential," "continue," "anticipates," "believes," "plans," "expects," "future" and "intends" and similar expressions which are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to numerous risks and uncertainties which are beyond the Company's control and difficult to predict and could cause actual results to differ materially from the results expressed or implied by the statements. Risks and uncertainties that could cause actual results to differ materially from such statements and may adversely impact the Company's financial condition and results of operations include: All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements and risk factors. Forward-looking statements contained in this press release reflect the Company's view only as of the date of this press release. The Company undertakes no obligation, other than as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In evaluating the Company's financial results and forward-looking statements, you should carefully consider the risks and uncertainties more fully described in the "Risk Factors" section or other sections in its reports filed with the SEC including the most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Non-GAAP Measures and Identical Sales Non-GAAP Measures. EBITDA, Adjusted EBITDA, Adjusted net income, Adjusted net income per Class A common share and Net debt ratio (collectively, the "Non-GAAP Measures") are performance measures that provide supplemental information the Company believes is useful to analysts and investors to evaluate its ongoing results of operations, when considered alongside other GAAP measures such as net income, operating income, gross margin, and net income per Class A common share. These Non-GAAP Measures exclude the financial impact of items management does not consider in assessing the Company's ongoing core operating performance, and thereby provide useful measures to analysts and investors of its operating performance on a period-to-period basis. Other companies may have different definitions of Non-GAAP Measures and provide for different adjustments, and comparability to the Company's results of operations may be impacted by such differences. The Company also uses Adjusted EBITDA and Net debt ratio for board of director and bank compliance reporting. The Company's presentation of Non-GAAP Measures should not be construed as an inference that its future results will be unaffected by unusual or non-recurring items. Identical Sales. As used in this earnings release, the term "identical sales" includes stores operating during the same period in both the current fiscal year and the prior fiscal year, comparing sales on a daily basis. Direct to consumer digital sales are included in identical sales, and fuel sales are excluded from identical sales.   View source version on businesswire.com: https://www.businesswire.com/news/home/20260414352692/en/ Contacts For Investor Relations, contact [email protected] For Media Relations, contact [email protected]

View stock analysis, news, and events for Albertsons Companies, Inc.